Payment overview · 2025
General Payments
$245.99
12 reported records · 6 companies
Healthcare provider profile · identity verified
Angel Ruiz, MD
Allopathic & Osteopathic Physicians|Family Medicine · BRONX, NY · NPI 1982866521
Verified facts
What the public records show
CMS Open Payments records show Angel Ruiz, MD received $245.99 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 40.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Symbicort by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 296 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $100.37 | 40.8% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.84 | 26.4% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.44 | 10.3% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $20.05 | 8.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.34 | 7.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.95 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $245.99 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $100.37 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $100.37 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $64.84 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $64.84 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.44 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 296 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
71 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
65 | 33 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
296 | 61 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
48 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 828 | 228 |
| Diclofenac Sodium | Diclofenac Sodium | 734 | 241 |
| Gabapentin | Gabapentin | 600 | 169 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 574 | 148 |
| Lisinopril | Lisinopril | 538 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 507 | 139 |
| Omeprazole | Omeprazole | 442 | 161 |
| Famotidine | Famotidine | 433 | 122 |
| Fluticasone Propionate | Fluticasone Propionate | 400 | 128 |
| Metoprolol Succinate | Metoprolol Succinate | 348 | 92 |
| Montelukast Sodium | Montelukast Sodium | 302 | 87 |
| Ozempic | Semaglutide | 296 | 61 |
| Losartan Potassium | Losartan Potassium | 280 | 82 |
| Tamsulosin Hcl | Tamsulosin Hcl | 265 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 262 | 73 |
| Ammonium Lactate | Ammonium Lactate | 218 | 68 |
| Jardiance | Empagliflozin | 207 | 56 |
| Tizanidine Hcl | Tizanidine Hcl | 200 | 85 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 200 | 81 |
| Baclofen | Baclofen | 182 | 50 |
| Metformin Hcl | Metformin Hcl | 178 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 175 | 48 |
| Trulicity | Dulaglutide | 174 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 89 |
| Alendronate Sodium | Alendronate Sodium | 163 | 47 |
| Nifedipine Er | Nifedipine | 163 | 37 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 158 | 47 |
| Metformin Hcl Er | Metformin Hcl | 144 | 41 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 126 | 48 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 120 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 120 | 20 |
| Carvedilol | Carvedilol | 118 | 39 |
| Furosemide | Furosemide | 107 | 33 |
| Donepezil Hcl | Donepezil Hcl | 102 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 102 | 35 |
| Enalapril Maleate | Enalapril Maleate | 99 | 26 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 99 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 22 |
| Meloxicam | Meloxicam | 97 | 53 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 91 | 18 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 89 | 25 |
| Simvastatin | Simvastatin | 88 | 21 |
| Meclizine Hcl | Meclizine Hcl | 87 | 43 |
| Single Use Swab | Alcohol Antiseptic Pads | 87 | 33 |
| Tramadol Hcl | Tramadol Hcl | 86 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 83 | 31 |
| Azelastine Hcl | Azelastine Hcl | 82 | 21 |
| Novolog Flexpen | Insulin Aspart | 80 | 20 |
| Celecoxib | Celecoxib | 78 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 76 | 14 |
| Ezetimibe | Ezetimibe | 74 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 73 | 30 |
| Chlorthalidone | Chlorthalidone | 71 | 20 |
| Farxiga | Dapagliflozin Propanediol | 71 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 22 |
| Vascepa | Icosapent Ethyl | 70 | 15 |
| Finasteride | Finasteride | 69 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 21 |
| Myrbetriq | Mirabegron | 66 | 18 |
| Tradjenta | Linagliptin | 66 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 65 | 33 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 65 | 22 |
| Trazodone Hcl | Trazodone Hcl | 63 | 19 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 60 | 12 |
| Eliquis | Apixaban | 59 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 57 | 12 |
| Clotrimazole | Clotrimazole | 54 | 18 |
| Folic Acid | Folic Acid | 54 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 54 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 26 |
| Incruse Ellipta | Umeclidinium Bromide | 51 | 13 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 50 | 16 |
| Memantine Hcl | Memantine Hcl | 50 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 13 |
| Topiramate | Topiramate | 49 | suppressed |
| Ibuprofen | Ibuprofen | 48 | 25 |
| Lactulose | Lactulose | 48 | 19 |
| Rybelsus | Semaglutide | 48 | 16 |
| Januvia | Sitagliptin Phosphate | 47 | 15 |
| Movantik | Naloxegol Oxalate | 47 | suppressed |
| Fluconazole | Fluconazole | 46 | 21 |
| Spironolactone | Spironolactone | 45 | 14 |
| Naproxen | Naproxen | 44 | 20 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 44 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 17 |
| Mirtazapine | Mirtazapine | 41 | 16 |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 40 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | 13 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 37 | 13 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Ketoconazole | Ketoconazole | 36 | 19 |
| Sucralfate | Sucralfate | 36 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 21 |
| Glimepiride | Glimepiride | 35 | suppressed |
| Procto-Med Hc | Hydrocortisone | 34 | 15 |
| Glipizide Er | Glipizide | 33 | suppressed |
| Levemir Flexpen | Insulin Detemir | 33 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Praluent Pen | Alirocumab | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Prednisone | Prednisone | 29 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Cilostazol | Cilostazol | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Gemtesa | Vibegron | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Linzess | Linaclotide | 26 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Zafirlukast | Zafirlukast | 26 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | 11 |
| Synjardy | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 18 |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Nyamyc | Nystatin | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Hydroxyurea | Hydroxyurea | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Mesalamine | Mesalamine | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $245.99 · 12 records | Novo Nordisk Inc | INGREZZA, LEQVIO, OTEZLA, Ozempic, REPATHA, Rybelsus, TEZSPIRE, Veozah | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error